Uncontrolled hypocalcemia, hypomagnesemia, hyponatremia or hypokalemia defined as less than the lower limit of normal for the institution despite adequate electrolyte supplementation
Uncontrolled hypomagnesemia, hypokalemia or hypocalcemia, defined as values below the lower limit of normal (LLN) for the institution despite adequate electrolyte supplementation or management
Uncontrolled electrolyte disorders that can compound the effects of QTc-prolonging drug (e.g. hypocalcemia, hypokalemia, hypomagnesemia)
Non-manageable electrolyte imbalances including hypokalemia, hypocalcemia, or hypomagnesemia (Grade 2 or greater based on NCI-CTCAE v 4.03).
Hypokalemia or hypomagnesemia if it cannot be corrected
Uncontrolled hyponatremia, syndrome of inappropriate antidiuretic hormone secretion (SIADH), hypokalemia, hyperkalemia, hypomagnesemia or hypermagnesemia
Significant electrolyte imbalance prior to enrollment (note that patients may be supplemented to achieve acceptable electrolyte values):\r\n* Hypomagnesemia < 1.2 mg/dL or 0.5 mmol/L\r\n* Hypocalcemia < 8.0 mg/dL or 2.0 mmol/L\r\n* Hypokalemia < 3.0 mmol/L
Significant electrolyte imbalance prior to enrollment (note that patients may be supplemented to achieve acceptable electrolyte values):\r\n* Hypomagnesemia < 1.2 mg/dL or 0.5 mmol/L\r\n* Hypokalemia < 3.0 mmol/L
Hypokalemia
Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation
Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation are excluded from this study
Any clinically significant electrolyte imbalance, particularly hypokalemia and hypomagnesemia, should be corrected before treatment
Significant electrolyte imbalance prior to enrollment:\r\n* Hypomagnesemia < 1.2 mg/dL or 0.5 mmol/L\r\n* Hypocalcemia < 8.0 mg/dL or 2.0 mmol/L\r\n* Hypokalemia < 3.0 mmol/L
Known hypoparathyroidism, pseudohypoparathyroidism, or vitamin D deficiency, or\n             clinical evidence of other conditions known to associated with hypocalcemia,\n             including:, hypoalbuminemia, hyperphosphatemia, hypomagnesemia
Electrolyte abnormalities (particularly hypokalemia or hypomagnesemia)
Subjects with hypokalemia and hypomagnesemia at Screening (defined as values below lower limit of normal [LLN]).
Uncontrolled electrolyte disorders that can compound the effects of a QTc-prolonging drug (e.g., hypocalcemia, hypokalemia, hypomagnesemia)
Uncontrolled electrolyte disorders (eg, hypocalcemia, hypokalemia, hypo¬magnesemia).
Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia.
Patient with electrolyte abnormality deemed clinically significant by the investigator (e.g., hypokalemia, hypomagnesemia, hypophosphatemia, hyperkalemia, hypocalcemia, hyponatremia) unless the level can be corrected to normal levels prior to initiating study drug
Risk factors for Torsades de Pointe (TdP) including uncorrected hypokalemia or hypomagnesemia, history of cardiac failure, or history of clinically significant/symptomatic bradycardia
Significant electrolyte imbalance prior to enrollment (note that patients may be supplemented to achieve acceptable electrolyte values):\r\n* Hypomagnesemia < 1.2 mg/dL or 0.5 mmol/L\r\n* Hypocalcemia < 8.0 mg/dL or 2.0 mmol/L\r\n* Hypokalemia < 3.0 mmol/L
Subject has hypokalemia and hypomagnesemia at Screening (defined as values below institutional lower limit of normal [LLN]).
REGISTRATION EXCLUSION CRITERIA: Uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, or hypokalemia defined as less than the lower limit of normal for the institution despite adequate electrolyte supplementation
Subjects with hypokalemia or hypomagnesemia if it cannot be corrected prior to dasatinib administration
Subject has hypokalemia or hypomagnesemia at screening.
Electrolyte abnormality that has not responded to correction, including hypokalemia or hypocalcemia less than the lower limit of normal, or hyperkalemia or hypercalcemia greater than the upper limit of normal (ULN).
At increased risk for developing prolonged QT interval, including hypokalemia or hypomagnesemia, unless corrected to within normal limits prior to first dose of SNX-• Chronic diarrhea.
Participants with evidence of electrolyte imbalance such as hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia, hypomagnesemia, and hypermagnesemia of Grade > 1 intensity, as per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0, prior to dosing on Cycle 1 Day 1. Treatment for correction of electrolyte imbalances is permitted to meet eligibility
Any clinically significant electrolyte imbalance, particularly hypokalemia and hypomagnesemia, should be corrected before treatment
Patients with a history of existing hypercalcemia, hypocalcemia, hypermagnesemia or hypomagnesemia that is not corrected despite supplementation
Subject with hypokalemia and hypomagnesemia at screening (defined as values below LLN).